Abstract
Background. Timely diagnosis of recurrence of malignant tumors of the ovaries can improve treatment outcomes.
Purpose – determine the feasibility of using the tumor marker HE-4 in case of recurrence of malignant ovarian tumors.
Materials and methods. To analyze the levels of HE-4 and CA-125 in patients with recurrence of malignant ovarian tumors and determine the feasibility of using HE-4 at this stage of monitoring, 29 patients with known indicators of HE-4 and CA-125 at the time of recurrence and their baseline data were selected.
Results and discussion. The paper presents the results of the study of the HE-4 and CA-125 tumor markers levels in 29 patients with a proven recurrence of malignant ovarian neoplasms depending on the timing of its appearance – up to 12 months (n = 9), 13–24 months (n = 11) and after 24 months (n = 9). The values of the tumor-associated HE-4 marker were decreased during the relapse compared to baseline expression levels. When analyzing of the HE-4 serum, their significant difference was revealed only in the event of relapse in the period of up to one year (1207.00 pmol/l) from recurrence rates in the periods of 13–24 and of over 24 months (567.00 and 655.50 pmol/l, respectively).
Conclusions. Only the baseline expression of HE-4 is prognostically significant for determining the timing of recurrence of ovarian malignancies.
Publisher
Institute for Medical Radiology and Oncology of NAMS of Ukraine
Subject
Radiology Nuclear Medicine and imaging,Oncology,Education,Radiological and Ultrasound Technology
Reference18 articles.
1. Fedorenko ZP, Gulak LO, Mihajlovich YUJ et al. Editors. Rak v Ukrayinі, 2018–2019. [Cancer in Ukraine, 2018–2019]. Morbidity, mortality, indicators of oncology service activity. Bulletin of National Cancer Registry of Ukraine. 2020;21:123. (In Ukrainian).
2. Aksel EM. Statystyka zlokachestvennykh novoobrazovanyi zhenskoi polovoi sfery. [Statistics of Malignant Tumors of Female Reproductive System]. Oncogynecology. 2012;1:18–24. (In Russian).
3. Serheeva NS, Marshutyna NV, Alentov YY et al. Serolohycheskye opukholeassotsyyrovannye markery CA-125 y HE-4 u bolnykh rakom yaychnykov. [Serum tumor markers СА125 and НЕ4 in ovary cancer patients]. Problems in Oncology. 2013;59(2):12– 21. (In Russian). DOI: https://doi.org/10.18722/VO201359212-21
4. Liu PY, Alberts DS, Monk BJ et al. An early signal of CA‑125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J. Clin. Oncol. 2007;25(24):3615–20. (In English). DOI: https://doi.org/10.1200/JCO.2006.09.4540
5. Stewart L, Advanced Ovarian Cancer Trialists Group. Chemotherapy for Advanced Ovarian cancer. Advanced Ovarian Cancer Trialists Group. Cochrane Database of Sys. Revs. 2002;4:10. (In English). DOI: https://doi.org/10.1002/14651858.CD001418